Citations (31)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Weili Xue, Weiming Li, Tiantian Zhang, Zhaoming Li, Yingjun Wang, Yajuan Qiu, Yuanyuan Wang, Changying Chen, Dongjun Fu & Mingzhi Zhang. (2019) Anti-PD1 up-regulates PD-L1 expression and inhibits T-cell lymphoma progression: possible involvement of an IFN-γ-associated JAK-STAT pathway. OncoTargets and Therapy 12, pages 2079-2088.
Read now
Read now
Wei Zhang, Jing Wang, Yanfang Wang, Fei Dong, Mingxia Zhu, Wenli Wan, Haishen Li, Feifei Wu, Xinxing Yan & Xiaoyan Ke. (2015) B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells. OncoTargets and Therapy 8, pages 1721-1733.
Read now
Read now
Articles from other publishers (29)
Cosimo Di Raimondo, Belen Rubio‐Gonzalez, Joycelynne Palmer, Dennis D. Weisenburger, Jasmine Zain, Xiwei Wu, Zhen Han, Steven T. Rosen, Joo Y. Song & Christiane Querfeld. (2022) Expression of immune checkpoint molecules programmed death protein 1, programmed death‐ligand 1 and inducible T‐cell co‐stimulator in mycosis fungoides and Sézary syndrome: association with disease stage and clinical outcome*. British Journal of Dermatology 187:2, pages 234-243.
Crossref
Crossref
Bita Amir Taghavi, Nazila Alizadeh, Hossein Saeedi, Noora Karim Ahangar, Afshin Derakhshani, Khalil Hajiasgharzadeh, Nicola Silvestris, Behzad Baradaran & Oronzo Brunetti. (2022) Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. Molecules 27:11, pages 3545.
Crossref
Crossref
Joanna Kopecka, Iris C. Salaroglio, Elizabeth Perez-Ruiz, Ana Bela Sarmento-Ribeiro, Simona Saponara, Javier De Las Rivas & Chiara Riganti. (2021) Hypoxia as a driver of resistance to immunotherapy. Drug Resistance Updates 59, pages 100787.
Crossref
Crossref
Hongyan Cheng, Liju Zong, Yujia Kong, Xiaoyu Wang, Yu Gu, Wei Cang, Jun Zhao, Xirun Wan, Junjun Yang & Yang Xiang. (2021) Camrelizumab plus apatinib in patients with high-risk chemorefractory or relapsed gestational trophoblastic neoplasia (CAP 01): a single-arm, open-label, phase 2 trial. The Lancet Oncology 22:11, pages 1609-1617.
Crossref
Crossref
Walaa Ghanam & Shaimaa M. M. Bebars. (2021) Cluster of Differentiation 274 Antigen Immunohistochemical Expression in Tumor and Peri-tumor Cells of Hodgkin and Non-Hodgkin Lymphoma and Clinicopathological Relation (Single-center Study). Open Access Macedonian Journal of Medical Sciences 9:A, pages 1011-1018.
Crossref
Crossref
Laura Jimbu, Oana Mesaros, Cristian Popescu, Alexandra Neaga, Iulia Berceanu, Delia Dima, Mihaela Gaman & Mihnea Zdrenghea. (2021) Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?. Pharmaceuticals 14:4, pages 288.
Crossref
Crossref
Katie Hudson, Neil Cross, Nicola Jordan-Mahy & Rebecca Leyland. (2020) The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. Frontiers in Immunology 11.
Crossref
Crossref
Stephen D. Smith, Brian G. Till, Mazyar S. Shadman, Ryan C. Lynch, Andrew J. Cowan, Qian V. Wu, Jenna Voutsinas, Heather A. Rasmussen, Katherine Blue, Chaitra S. Ujjani, Andrei Shustov, Ryan D. Cassaday, Jonathan R. Fromm & Ajay K. Gopal. (2020) Pembrolizumab with R‐CHOP in previously untreated diffuse large B‐cell lymphoma: potential for biomarker driven therapy. British Journal of Haematology 189:6, pages 1119-1126.
Crossref
Crossref
Chie Kudo-Saito. (2020) A possible paradigm shift from targeting immune checkpoint pathways toward targeting oncoimmune drivers in cancer immunotherapyPrecision medicine創出に向けた免疫チェックポイント阻害からのパラダイムシフトの必要性. Journal of Japanese Society of Oral Oncology 32:4, pages 144-152.
Crossref
Crossref
Izumi Yamaguchi, Kohei Nakajima, Kenji Shono, Yoshifumi Mizobuchi, Toshitaka Fujihara, Eiji Shikata, Tadashi Yamaguchi, Keiko Kitazato, Oltea Sampetrean, Hideyuki Saya & Yasushi Takagi. (2020) Downregulation of PD-L1 via FKBP5 by celecoxib augments antitumor effects of PD-1 blockade in a malignant glioma model. Neuro-Oncology Advances 2:1.
Crossref
Crossref
Luis Veloza, Cristina Teixido, Natalia Castrejon, Fina Climent, Ana Carrió, Marta Marginet, Davide Soldini, Blanca González‐Farré, Inmaculada Ribera‐Cortada, Armando Lopez‐Guillermo, Eva González‐Barca, Adriana Sierra, Mileyka Herrera, Cándida Gómez, Adriana Garcia, Olga Balagué, Elias Campo & Antonio Martinez. (2019)
Clinicopathological evaluation of the programmed cell death 1 (PD1)/programmed cell death‐ligand 1 (PD‐L1) axis in post‐transplant lymphoproliferative disorders: association with Epstein–Barr virus,
PD‐L1
copy number alterations, and outcome
. Histopathology 75:6, pages 799-812.
Crossref
Crossref
Yilun Wu, Weiyu Chen, Zhi Ping Xu & Wenyi Gu. (2019) PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition. Frontiers in Immunology 10.
Crossref
Crossref
Yi Li, Gang Li, Tao Tao, Xing Kang, Chang Liu, Xu Zhang, Chunyi Wang, Chong Li & Xiangyang Guo. (2019) The μ-opioid receptor (MOR) promotes tumor initiation in hepatocellular carcinoma. Cancer Letters 453, pages 1-9.
Crossref
Crossref
Barbora Brodská, Petra Otevřelová, Cyril Šálek, Ota Fuchs, Zdenka Gašová & Kateřina Kuželová. (2019) High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations. International Journal of Molecular Sciences 20:11, pages 2823.
Crossref
Crossref
Xiaosheng Wu, Yanli Li, Xin Liu, Chunhua Chen, Susan M. Harrington, Siyu Cao, Tiancheng Xie, Tu Pham, Aaron S. Mansfield, Yiyi Yan, Eugene D. Kwon, Liewei Wang, Kun Ling & Haidong Dong. (2018) Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. Heliyon 4:12, pages e01039.
Crossref
Crossref
O. Annibali, A. Crescenzi, V. Tomarchio, A. Pagano, A. Bianchi, A. Grifoni & G. Avvisati. (2018) PD-1 /PD-L1 checkpoint in hematological malignancies. Leukemia Research 67, pages 45-55.
Crossref
Crossref
Lanfen Huo, Wenwen Wei, Shaoling Wu, Xindong Zhao, Chunting Zhao, Hongguo Zhao & Lingjie Sun. (2018) Effect of dihydroarteminin combined with siRNA targeting Notch1 on Notch1/c-Myc signaling in T-cell lymphoma cells. Experimental and Therapeutic Medicine.
Crossref
Crossref
Pauline Gravelle, Barbara Burroni, Sarah Péricart, Cédric Rossi, Christine Bezombes, Marie Tosolini, Diane Damotte, Pierre Brousset, Jean-Jacques Fournié & Camille Laurent. (2017) Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies. Oncotarget 8:27, pages 44960-44975.
Crossref
Crossref
Stephanie C. Casey, Virginie Baylot & Dean W. Felsher. (2017) MYC: Master Regulator of Immune Privilege. Trends in Immunology 38:4, pages 298-305.
Crossref
Crossref
Katrien Van Roosbroeck, Julio Finalet Ferreiro, Thomas Tousseyn, Jo-Anne van der Krogt, Lucienne Michaux, Barbara Pienkowska-Grela, Ivan Theate, Pascale De Paepe, Daan Dierickx, Chantal Doyen, Natalie Put, Jan Cools, Peter Vandenberghe & Iwona Wlodarska. (2016)
Genomic alterations of the
JAK2
and
PDL
loci occur in a broad spectrum of lymphoid malignancies
. Genes, Chromosomes and Cancer 55:5, pages 428-441.
Crossref
Crossref
FEIFEI WU, JING WANG & XIAOYAN KE. (2016) Knockdown of B7-H6 inhibits tumor progression and enhances chemosensitivity in B-cell non-Hodgkin lymphoma. International Journal of Oncology 48:4, pages 1561-1570.
Crossref
Crossref
Danielle M Lussier, John L Johnson, Pooja Hingorani & Joseph N Blattman. (2015) Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. Journal for ImmunoTherapy of Cancer 3:1.
Crossref
Crossref
N Epperla, T S Fenske, H M Lazarus & M Hamadani. (2015) Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?. Bone Marrow Transplantation 50:11, pages 1393-1404.
Crossref
Crossref
Joseph G. Taylor & John G. Gribben. (2015) Microenvironment abnormalities and lymphomagenesis: Immunological aspects. Seminars in Cancer Biology 34, pages 36-45.
Crossref
Crossref
Semra Paydas, Emine Bağır, Gulsah Seydaoglu, Vehbi Ercolak & Melek Ergin. (2015) Programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and EBV-encoded RNA (EBER) expression in Hodgkin lymphoma. Annals of Hematology 94:9, pages 1545-1552.
Crossref
Crossref
Toby A. Eyre & Graham P. Collins. (2015) Immune checkpoint inhibition in lymphoid disease. British Journal of Haematology 170:3, pages 291-304.
Crossref
Crossref
Loretta J. Nastoupil & Sattva S. Neelapu. (2015) Novel Immunologic Approaches in Lymphoma: Unleashing the Brakes on the Immune System. Current Oncology Reports 17:7.
Crossref
Crossref
LIJUAN HAN, FEIFEI LIU, RUPING LI, ZHAOMING LI, XINFENG CHEN, ZHIYUAN ZHOU, XUDONG ZHANG, TENGPENG HU, YI ZHANG, KEN YOUNG, SUKE SUN, JIANGUO WEN & MINGZHI ZHANG. (2014) Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncology Letters 8:4, pages 1461-1469.
Crossref
Crossref
Philippe ArmandArnon NaglerEdie A. WellerSteven M. DevineDavid E. AviganYi-Bin ChenMark S. KaminskiH. Kent HollandJane N. WinterJames R. MasonJoseph W. FayDavid A. RizzieriChitra M. HosingEdward D. BallJoseph P. UbertiHillard M. LazarusMarkus Y. MaparaStephanie A. GregoryJohn M. TimmermanDavid AndorskyReuven OrEdmund K. WallerRinat Rotem-YehudarLeo I. Gordon. (2013) Disabling Immune Tolerance by Programmed Death-1 Blockade With Pidilizumab After Autologous Hematopoietic Stem-Cell Transplantation for Diffuse Large B-Cell Lymphoma: Results of an International Phase II Trial. Journal of Clinical Oncology 31:33, pages 4199-4206.
Crossref
Crossref